COMMUNIQUÉS West-GlobeNewswire

AC Immune First Quarter 2026 Financial and Corporate Updates
30/04/2026
AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial of brain-penetrant small molecule NLRP3 inhibitor ACI-19764 with SAD/MAD results in healthy volunteers expected in H2 [...]
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
30/04/2026
WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies [...]
Option Care Health Announces Financial Results for the First Quarter Ended March 31, 2026
30/04/2026
BANNOCKBURN, Ill., April 30, 2026 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (the “Company” or “Option Care Health”) (Nasdaq: OPCH), the nation’s largest independent provider of home and alternate site infusion [...]
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
30/04/2026
~1.35 million total VOQUEZNA ® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net [...]
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
30/04/2026
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone [...]
Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments
30/04/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing which will result in a differentiated company focusing on metabolic and autoimmune pipeline assets with multiple important [...]
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
30/04/2026
Q1’26 Total Net Revenue of $317 Million, Up 19% YoY Q1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly [...]
Northwestern Medicine Opens $15 Million Center Expanding Advanced Gastrointestinal Care to Suburban Chicago
30/04/2026
The Center for Advanced Endoscopy offers some of the most advanced endoscopic procedures available in the United States WINFIELD, Ill., April 30, 2026 (GLOBE NEWSWIRE) -- Northwestern Medicine is expanding access to [...]
Royal Columbian Hospital begins patient recruitment in Arch Biopartners’ Phase II trial of LSALT peptide targeting CS-AKI
30/04/2026
TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that Royal Columbian Hospital (RCH) has begun patient recruitment in the [...]
EUROAPI_Contrat de liquidité
30/04/2026
Communiqué de presse Paris, 30 avril 2026 Programme de rachat d’actions Réduction de moyen au contrat de liquidité avec Kepler Cheuvreux Par contrat en date du 30 mai 2022, la société EUROAPI (ISIN: FR0014008VX5) a [...]
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
30/04/2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
EUROAPI_Liquidity Contract
30/04/2026
Press Release Paris 30 avril, 2026 Share buyback program Reduction in the Resources Allocated under the Liquidity Contract with Kepler Cheuvreux By agreement dated 30 May 2022, EUROAPI (ISIN: FR0014008VX5) entrusted [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04/2026
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, [...]
Santhera Proposes Dr. Srishti Gupta as New Member of the Board of Directors
30/04/2026
Ad hoc announcement pursuant to Art. 53 LR. Pratteln, Switzerland, April 30, 2026 – Santhera Pharmaceuticals (SIX: SANN) proposes to elect Dr. Srishti Gupta, MD, MPP, MPhil, as an Independent Director at the upcoming [...]
Nicox Provides Full Year 2025 Financial Results and Corporate Update
30/04/2026
Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024) NCX 470 U.S. New [...]
Addex Reports Full Year 2025 Financial Results and Provides Corporate Update
30/04/2026
GABAB PAM chronic cough candidate continued towards clinic after demonstrating robust anti-tussive activity in multiple disease models Continued to reposition dipraglurant mGlu5 NAM for brain injury recovery Entered [...]
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
30/04/2026
Communiqué de presse Nicox annonce ses résultats financiers 2025 et fait un point sur son activité Chiffre d’affaires de 16,8 millions d’euros (7,9 millions d’euros en 2024) Perte nette significativement réduite à 2,4 [...]
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
30/04/2026
New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DME Key data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing treatment burden [...]

Pages